Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

Christos Markopoulos, Urania Dafni, John Misitzis, Vasilios Zobolas, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Grigorios Xepapadakis, John Papadiamantis, Basileios Venizelos, Zoh Antonopoulou, Helen Gogas, Christos Markopoulos, Urania Dafni, John Misitzis, Vasilios Zobolas, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Grigorios Xepapadakis, John Papadiamantis, Basileios Venizelos, Zoh Antonopoulou, Helen Gogas

Abstract

Introduction: Extended adjuvant endocrine therapy for breast cancer with aromatase inhibitors may potentially alter the lipid profile of postmenopausal patients and thus increase the risk of developing cardiovascular disease. In this study, a subprotocol of the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial, we compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile of postmenopausal patients with operable breast cancer, in the adjuvant setting, with that of observation alone after completion of 5 to 7 years of primary treatment with tamoxifen.

Methods: In this open-label, randomized, parallel-group study, 411 postmenopausal patients with operable breast cancer, who had been treated with tamoxifen for 5 to 7 years, were randomized to either 5 additional years of exemestane (25 mg/day; n = 211) or observation only (n = 200). Assessments of total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total serum triglycerides (TRG) were performed at baseline and then during each follow-up visit, performed at either 6 or 12 months, according to the center's clinical practice, until completing 24 months in the study.

Results: TC and LDL levels increased significantly across time for both arms; TC increase was more pronounced for the observation arm, and that was sustained up to 24 months. HDL levels decreased significantly across time for the exemestane arm, whereas no significant change was detected across time for the observation arm. Triglyceride levels decreased significantly across time on both arms, with no difference detected in changes from baseline between the exemestane and the observation arms.

Conclusions: Exemestane lacks the beneficial effect of tamoxifen on lipids; however, sequential adjuvant treatment with exemestane in postmenopausal breast cancer patients after cessation of 5 to 7 years of tamoxifen does not appear to alter the lipid profile significantly compared with that of an observational arm.

Trial registration: ClinicalTrials.gov ID: NCT00810706.

Figures

Figure 1
Figure 1
Estimated mean values versus observed for total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (total log TRG).

References

    1. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829–1846. doi: 10.1093/jnci/91.21.1829.
    1. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229–238. doi: 10.1002/cncr.11468.
    1. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–1670. doi: 10.1200/JCO.2007.13.5822.
    1. Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol. 2005;95:3–119. doi: 10.1016/j.jsbmb.2005.04.014.
    1. Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2007:CD003370.
    1. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial: efficacy and safety update analyses. Cancer. 2003;98:1802–1810. doi: 10.1002/cncr.11745.
    1. Breast International Group (BIG) 1–98 Collaborative Group. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757. doi: 10.1056/NEJMoa052258.
    1. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Velde C van de. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092. doi: 10.1056/NEJMoa040331.
    1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271.
    1. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report, 2004. J Clin Oncol. 2005;23:619–629. doi: 10.1200/JCO.2005.09.121.
    1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–1144. doi: 10.1093/annonc/mdm271.
    1. NCCN Clinical Practice Guidelines in Oncology™
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0.
    1. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–690. doi: 10.1093/jnci/93.9.684.
    1. Jakesz R, Samonigg H, Greil R, Gnant M, Schmid M, Kwasny W, on behalf of the ABCSG Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) J Clin Oncol. 2005;23:10S. (#526, abstract)
    1. Mamounas E, Jeong J-H, Wickerham L, Smith R, Geyer C, Ganz P. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat. 2006;100(suppl 1):S22. (#49, abstract)
    1. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation. 1992;86:1046–1060.
    1. Kritchevsky SB. Dietary lipids and the low blood cholesterol-cancer association. Am J Epidemiol. 1992;135:509–520.
    1. National Center for Chronic Disease Prevention and Health Promotion. 2004.
    1. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987;114:413–419. doi: 10.1016/0002-8703(87)90511-4.
    1. Bass KM, Newschaffer CJ, KIag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209–2216. doi: 10.1001/archinte.153.19.2209.
    1. Korhonen T, Savolainen MJ, Ikäheimo M, Linnaluoto MK, Kervinen K, Kesäniemi VA. Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis. 1996;127:213–220. doi: 10.1016/S0021-9150(96)05958-8.
    1. Levi F, Randimbison L, Te VC, La Vecchia C. Long-term mortality of women with a diagnosis of breast cancer. Oncology. 2002;63:266–269. doi: 10.1159/000065475.
    1. Goss PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer. 1999;6:325–332. doi: 10.1677/erc.0.0060325.
    1. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037.
    1. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. HRT: an analysis of benefits, risks, and costs. Br Med Bull. 1992;48:368–400.
    1. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534–1539. doi: 10.1093/jnci/86.20.1534.
    1. Elisaf M, Bairaktari E, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res. 1996;16:2725–2728.
    1. Markopoulos C, Chrissochou M, Antonopoulou Z, Xepapadakis G, Papadiamantis J, Tzoracoleftherakis E, Gogas H. Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment. Oncology. 2006;70:301–305. doi: 10.1159/000096251.
    1. Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E, Coombes RC. Phase I and endocrine study of exemestane (FCE24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 1992;52:5933–5939.
    1. Giudici D, Ornati G, Briatico G, Buzzeti F, Lambardi P, di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE24304): a new irreversible aromatase inhibitor. J Steroid Biochem. 1988;30:391–394. doi: 10.1016/0022-4731(88)90129-X.
    1. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Velde CJ Van de, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570. doi: 10.1016/S0140-6736(07)60200-1. Erratum in: Lancet 2007, 369:906.
    1. Markopoulos C, Chrissochou M, Michailidou A, Tzoracoleftherakis E, Xepapadakis G, Papadiamantis J, Misitzis J, Zobolas V, Bafaloukos D, Gogas H. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs. 2005;16:879–883. doi: 10.1097/01.cad.0000173478.12981.e1.
    1. Laird NM, Ware JH. Random effect models for longitudinal data. Biometrics. 1982;38:963–974. doi: 10.2307/2529876.
    1. Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefice S, Buzzoni R, Di Bartolomeo M, Di Leo A, Laffranchi A. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer. 1995;72:1007–1012.
    1. Di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC. Exemestane (FCE24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1992;43:137–143. doi: 10.1016/0960-0760(92)90198-R.
    1. Food and Drug Administration . Center for Drug Evaluation and Research application number NDA 20753 (Exemestane) Medical Review. Rockville, MD: FDA; 1999.
    1. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med. 1997;157:961–968. doi: 10.1001/archinte.157.9.961.
    1. Engan T, Krane J, Johannessen DC, Lønning PE, Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy: lipid measurements and nuclear magnetic imaging (NMR) spectroscopy. Breast Cancer Res Treat. 1995;36:287–297. doi: 10.1007/BF00713400.
    1. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951: "randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients". Ann Oncol. 2004;15:211–217. doi: 10.1093/annonc/mdh064.
    1. Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006;95:153–158. doi: 10.1038/sj.bjc.6603258.
    1. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126–5137. doi: 10.1200/JCO.2005.07.097.
    1. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat. 2005;93:61–66. doi: 10.1007/s10549-005-3783-0.
    1. Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G, Gogas H. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol. 2009;20:49–55. doi: 10.1093/annonc/mdn545.
    1. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Ann Oncol. 2005;16:707–715. doi: 10.1093/annonc/mdi158.
    1. McCloskey E, Eastell R, Lakner G, Miyamoto A, Clack G. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat. 2005;94(suppl 1):S101. Abstract 2052.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅